

1 **Article type:** Original article

2 **Title: “Genomic and phenotypic characterization of Investigator Global Assessment (IGA)**
3 **scale based endotypes in atopic dermatitis”**

4 Sandra P Smieszek¹, Bartłomiej Przychodzen¹, Sarah E Welsh¹, Jennifer Brzezynski¹, Alyssa Kaden¹,
5 Michael Mohrman¹, Jingyuan Wang¹, Changfu Xiao¹, Sonja Ständer², Gunther Birznieks¹, Christos
6 Polymeropoulos¹, Mihael H Polymeropoulos¹

7 ¹Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

8 ²Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany

9

10 Twitter handle: @vandapharma

11

12 **Corresponding author:**

13 Sandra P. Smieszek
14 2200 Pennsylvania NW, Suite 300-E
15 Washington, DC 20037
16 Email: sandra.smieszek@vandapharma.com

17

18 **Funding sources:** Vanda Pharmaceuticals

19

20 **Conflicts of Interest:** SPS is an employee of Vanda and a stockholder. BPP is an is an employee
21 of Vanda and a stockholder. SEW is an employee of Vanda and a stockholder. JB is an
22 employee of Vanda and a stockholder. AK is an employee of Vanda and a stockholder. MM is an
23 employee of Vanda and a stockholder. CX is an employee of Vanda and a stockholder. CP is an
24 employee of Vanda and a stockholder. GB is an employee of Vanda and a stockholder. MHP is
25 Chief Executive Officer of Vanda.

26

27 IRB approval status: Reviewed and approved by Advarra IRB; Pro00025510

28

29 Clinicaltrials.gov listing: NCT03568331

30

31 **Reprint requests:** Sandra Smieszek

32

33 **Manuscript word count:** 2534

34 **Abstract word count:** 195

35 **Capsule summary word count:** 48

36 **References:** 3

37 **Figures:** 5

38 Supplementary **Figures:** 4

39 **Tables:** 1

40 Supplementary tables: 2

41 Attachments: 1

42 **Keywords:** Atopic dermatitis; itch; endotypes; whole genome sequencing; cytokines

43

44 **Abbreviations**

AD	Atopic Dermatitis
EDC	Epidermal Differentiation Complex
EOS	Eosinophils
FLG	Filaggrin
IGA	Investigator's Global Assessment
IL	Interleukin
LOF	Loss-of-Function
NK1R	Neurokinin-1 Receptor
SCORAD	SCORing Atopic Dermatitis
SP	Substance P
vIGA-AD	Validated Investigator Global Assessment for Atopic Dermatitis

45

46

47 **ABSTRACT**

48 *Background:* Atopic dermatitis (AD) is a heritable and heterogeneous inflammatory chronic skin
49 disorder. Utilizing decision tree/supervised learning of extensive clinical, molecular and genetic
50 data, we aimed to define distinct AD endotypes.

51 *Methods:* Deep phenotyping and whole-genome sequencing was performed on samples obtained
52 from participants of EPIONE, a randomized-controlled phase III study in AD patients with
53 severe pruritus comprising mild (23%), moderate (64%) and severe (13%) AD as determined by
54 AD Investigator Global Assessment scale . Three categories of analysis were performed: clinical
55 associations, lab value associations (EOS, IgE, cytokines) and genetic analysis of whole-genome
56 sequencing data

57 *Results:* Based on a decision tree, we found that five clinical features from the SCORing Atopic
58 Dermatitis (SCORAD) Index can accurately differentiate between IGA severities. We observe a
59 significant difference between severity and eosinophil counts ($p<0.001$), IgE ($p<0.001$) and
60 *Filaggrin (FLG)* LOF frequency (OR 2.3, CI 1.6-3.2, $p<0.0001$) as well as interleukin pathway
61 genes, specifically IL5RA variants differentiating the groups.

62 *Conclusion:* Our results suggest significant differences between severity groups across a number
63 of features appear to constitute distinct endotypes with likely distinct causative factors. Differing
64 underlying pathophysiology's indicate endotype knowledge is critical to help guide therapeutic
65 approaches to AD.

66

67 **Capsule summary**

- 68 • AD is a heritable and heterogeneous skin disorder that makes the ‘one size fits all’
69 therapeutic approach suboptimal for patients with AD.
- 70 • We attempted to define AD endotypes based on clinical, molecular, and genetic
71 characteristics. Clinical, CBC, and genetic associations all tend to suggest existence of
72 separate endotypes.

73 **Introduction**

74 Atopic dermatitis (AD) is a complex and heterogeneous, highly heritable, chronic-relapsing,
75 inflammatory skin disorder. AD affects 7.3% of US adults^{1,2}. The genetic background of AD is
76 complex and likely composed of a mixture of rare and common variants. The heritability of AD
77 is estimated to be around 75%². Studies have shown that there are genetic factors specific to AD
78 beyond those for general atopy^{3,4}. AD is manifested by a wide range of symptoms and
79 significantly impacts quality of life. Flares are usually characterized by extreme pruritus of red,
80 rough, flaky and often fissured regions of the skin, that over time thicken². Chronic pruritus,
81 lasting more than 6 weeks, is a key feature associated with AD. The extent of skin lesions and
82 other physical symptoms vary within this patient population and can be diagnosed as mild,
83 moderate, or severe as defined by the Investigator Global Assessment scale for Atopic Dermatitis
84 (vIGA-ADTM). The etiology is likely resultant from an interaction between the genetically
85 determined skin barrier, immune system dysregulation, and the environmental triggers².

86 One of the main functions of the skin is to act as a barrier between the individual and the
87 environment, preventing water loss and at the same time preventing pathogen and allergen
88 entry⁵. Skin barrier dysfunction is a key clinical feature of AD, as this facilitates penetration of
89 allergens, immunological dysfunction, and consequently an increased risk of developing
90 eczema^{5,6}. The skin barrier dysfunction has, among others, been associated with the etiology of
91 the itch-scratch cycle⁷. In addition, genes encoding skin barrier proteins have been shown to play
92 a role in the heritability of AD^{8,9}. Loss-of-function (LOF) variants resulting in
93 aberrant *FLG* production, constitute the best-known AD gene-association and have been shown
94 to predispose individuals to AD^{10,11}. Individuals harboring *FLG* LOF variants manifest clinical
95 features such as dry and fissured skin. LOF variants in *FLG* are associated with lower levels of

96 natural moisturizing factors in AD¹². Additional genes involved in skin barrier function,
97 including epidermal differentiation complex (EDC) proteins, are thought to have a potential role
98 in AD. The EDC encodes proteins critical to the proper development of keratinocytes and normal
99 formation of the skin barrier¹³. Downregulation of EDC genes has also been implicated in
100 AD^{14,15,16,17}.

101 Disrupted skin barrier promotes penetration of allergens, immunological dysfunction, and
102 consequently an increased risk of developing eczema¹⁸. Critical features of the TH2 immune
103 response include local production of TH2 cytokines activation of eosinophils (EOS) and mast
104 cells, as well as production of IgE¹⁹. Ultimately T-cell subsets, including Th2/Th22 cells, are
105 upregulated in AD skin²⁰. Interestingly both lesional and nonlesional AD showed a highly
106 polyclonal T cell receptor pattern, insinuating the lasting presence of potentially pathogenic
107 memory T cells beyond clinically inflamed lesions²⁰. Ultimately dysregulation leads to increased
108 production of neuropeptides such as substance P (SP) released from primary sensory nerves in
109 the skin²¹. SP binds the neurokinin-1 receptor (NK1R) and MRGPRs²². Elevated SP levels have
110 been observed in the blood and lesional skin of AD patients, and have been correlated with itch
111 intensity, as shown in challenge studies and further reiterated in transcriptome analysis^{23,7}.
112 Elevated SP levels further elicit vasodilation of short duration leading to mast cell degranulation,
113 nerve growth factor expression in keratinocytes, and neurogenic inflammation associated with
114 erythema and pruritus²¹. Proof of concept studies have shown increases in itch resulting from
115 injected SP and expression of NK1R in keratinocytes, as well as reduction in itch resulting from
116 inhibition of NK1R. Pruritus, perpetuates scratching that further damages the skin barrier⁷.

117 Our work aimed to evaluate the effect of clinical manifestations, molecular levels and genetic
118 associations and cytokine levels to further understand the architecture and variability of AD as

119 assessed in subjects during baseline visit. We aim to discern whether degree of severity

120 recapitulates individual endotypes in AD.

121

122 **Results**

123 EPIONE, a multi-center, placebo-controlled, double-blind study, enrolled and randomly assigned
124 (1:1) 375 patients aged 18 to 70 with AD. Welsh et al., 2020 (manuscript under review)
125 describes the efficacy and safety results from EPIONE. At baseline, participants presented with a
126 range of disease severities from mild (23%) to moderate (64%), and severe (13%). Severity was
127 defined by Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM). For analysis,
128 milder AD was defined as IGA scores of 1 (1) or 2 (77) at baseline, while more severe AD was
129 defined as IGA scores of 3 (218) or 4 (33). In addition to deep phenotyping we obtained AD
130 samples for whole genome sequencing (n=765 entire study population, n=332 randomized
131 patients). **Table 1** shows demographic and clinical characteristics of the studied cohort at
132 baseline. **Figure 1** depicts the baseline clinical and lab measurements across IGA groups. We
133 examine each sub-component in depth in the sections that follow.

134 **Clinical Association**

135 We collected extensive clinical information using the SCORAD index including total area
136 involved, intensity, and subjective measurements^{24, 25}. As expected, we observe that mild AD
137 presents with fewer lesions, mild erythema, and minimal induration/papulation or
138 oozing/crusting. In contrast, severe AD presents with a larger number of erythematous lesions
139 associated with significant induration/papulation, oozing/crusting. Importantly, we observed that
140 the interaction between three most informative variables (Edema/Papules, Erythema and Total
141 Area Affected) can classify patients by disease severity. The most severe patients present almost
142 exclusively with highest SCORAD Edema/Papules score (3 on a 0-3 scale) or SCORAD
143 Erythema (3 on a 0-3 scale). Utilizing only those two variables we can accurately identify 35.8%
144 of IGA3/4 with only 2.5% of IGA1/2 falling into that category (**Figure 2A-B**). Remaining 64.2%

145 of IGA3/4 patients are more difficult to distinguish from IGA1/2. There is a clear separation of
146 the remaining IGA3/4 patients by the SCORAD Total Affected Area (**Figure 2C**).

147 We performed a series of classification and regression analyses to understand the underlying
148 nature of the severity subgroups utilizing multiple clinical variables at once. We focus our
149 analysis using classification trees. Based on a series of five clinical features from the SCORAD
150 scale, we were able to accurately differentiate between IGA 1/2 versus IGA 3/4. We obtained a
151 robust classification using SCORAD Total Affected Area (%), Edema/Papules, Erythema,
152 Lichenification, and Excoriation. Five-fold cross-validation classification (J48) yields weighted
153 83.8% precision and 80.1% recall and a large AUC 0.830. **Supplementary Figure 1** displays the
154 actual tree (J48) revealing the cutoffs and splits.

155 **Eosinophils and IgE**

156 Motivated by the hypothesis that atopy is key in the expression of AD, we evaluated the role of
157 counts of eosinophils and levels of IgE and their association with the clinical expression of AD.
158 We evaluated lab values (EOS, IgE, systemic cytokines) that may differentiate milder from more
159 severe AD. We detect a significant association between IGA and EOS levels. We have shown
160 that more severe AD (IGA3/4) is associated with significantly higher counts of eosinophils as
161 compared to milder AD (IGA1/2) (**Figure 1**), an effect that is significant (Mann-Whitney
162 $p < 0.01$). The effect is persistent in an extended screening cohort of 765 samples. Moreover, there
163 is a significant difference between IGA 3 and 4 in the EOS levels ($p < 0.0008$) and 1/2 vs. 4
164 ($p < 0.0001$). This suggests that systemic eosinophil levels are increasingly correlated across the
165 IGA severity scale. All but 3 cases of the 32 cases above 0.5 are moderate to severe AD subjects

166 (29/282 of IGA3/4 and only 3/79 IGA1/2). Additionally, we report a significant difference in
167 distribution of patients with elevated serum IgE (**Figure 1D**, ≥ 100 IU/mL, $p < 0.001$).

168 **Genetic landscape of AD endotypes**

169 We performed whole genome sequencing of the entire study population ($n=765$). We
170 investigated the incidence of all *FLG* LOF variants in the genomes of the EPIONE study
171 patients, and compared them with the whole genome sequences of a control population ($n=316$).
172 of healthy volunteers as well as individuals from gnomAD database. More severe AD is
173 associated with a higher prevalence of *FLG* LOF variants ($p < 0.0001$, OR: 2.3, CI: 1.6-3.2). This
174 is significant enrichment as compared to milder ($p=0.99$, OR: 0.89, CI: 0.3-2.0). Milder AD has
175 incidence of LOF *FLG* variants comparable to normal population as defined by gnomAD and an
176 internal set of controls (IGA1/2: 6.4%, Vanda Controls: 6.2%, GnomAD: 8.4%) whereas the
177 moderate to severe subgroup has an elevated frequency of LOF *FLG* variants (IGA3/4: 17.7%).
178 This is contrary to the general observation that AD cases have higher prevalence of *FLG*
179 mutations than the control population, as this effect seems to be specific to IGA3/4 subjects. The
180 variants detected are depicted on **Figure 3** which displays the location of individual LOF
181 variants in both endotypes. We have now showed that the increased frequency can be ascribed to
182 the severe AD subtypes. The results are consistent for EDC gene variants. Furthermore, we
183 detect higher frequency if individuals with two or more *FLG* mutations in the severe group as
184 well as incidence of cases with CNV within the *FLG* gene present in the IGA3/4. The allelic
185 frequency of the two prevalent *FLG* LOF variants, p.R501* and p.S761fs as well as the OR is
186 displayed on panel B of **Figure 3**.

187 ***IL5RA* gene rare variants differentiate between IGA subgroups**

188 We have performed *in silico* interleukin (IL) screen using gene-centric collapsing analysis on a
189 pathway of IL genes as defined by GO terms, comprised of 96 genes. In a rare variant analysis
190 we obtain a significant result after conservative multiple hypothesis testing in IL5RA as
191 differentiating between the two severity groups. Direction of effect is consistent with a higher
192 EOS levels observed in IGA3/4. Binding of IL-5 to the α -subunit of the IL5Ra promotes the
193 heterodimerization of α and β subunits. As a result, many signal transduction pathways
194 are activated, including JAK/STAT modules, MAPK, Pi3K, and NF- κ B. The stimulation of these
195 kinases and TFs drives the expression of key genes responsible for differentiation, survival,
196 degranulation, adhesion, and recruitment of eosinophils. Furthermore through whole genome
197 sequence analysis we have also discovered that polymorphisms in the IL5Ra gene are associated
198 with higher count of eosinophils in this population of AD patients. The IL5Ra rare variant
199 rs200005614 associates with significantly higher level of EOS consistent with the effect
200 observed. Previously other variants were found to be associated with EOS such as *IL5RA*
201 *c.-5091G>A* which was shown to be associated with eosinophil count. *IL5RA* plays an
202 important role in coordinating the release of eosinophil and IgE production against antigens
203 leading to the development of atopy. The association of the IL5RA variants with the blood
204 eosinophil counts and the severe IGA indicates that the IL5RA gene has a role for controlling
205 crucial role in eosinophil responses.

206 **Cytokines**

207 We measured a panel of systemic cytokines collected at baseline. We evaluated which cytokines
208 at baseline are above the normal ranges (as defined by clinical standards²⁶) and show the results
209 on a heatmap of ratios to reference range. This is displayed on **Figure 4** (log₂ ratio of cytokine to
210 a maximum value reported in reference range, red being above threshold levels levels). The

211 observed trends are suggestive of elevated levels of Th2 (IL-4, IL-5, and IL-13). Increased IL-5,
212 as well as IL-4 and IL-23 form a distinct, predominant group of patients (**Figure 4**).

213 Interestingly, there is a subgroup of patients that also have elevated IL-6, IL-8, and IL-13 (blue
214 ribbon highlight on **Figure 4**). IL-5 is produced by type 2 T helper cells and mast cells. It
215 stimulates B cell growth and increases immunoglobulin secretion, and primarily is the key
216 mediator of eosinophil activation. Its high expression has been previously associated with
217 chronic AD. It stimulates activated B cell and T cell proliferation, and differentiation of B cells
218 into plasma cells. IL-4 has been implicated in tissue inflammation and epidermal barrier
219 dysfunction²⁷. These patients have decreased IFN-gamma and IL-12 levels across all patients,
220 not limited to patients with elevated Th2. Whereas the main signature pattern (elevated IL-4, IL-
221 5, and IL-23) is still as abundant in IGAs 1/2 and even 3s, subjects defined as 4 lack a subgroup
222 of patients with high level of IL-6, IL-8, and IL-13. **Figure 5** displays the cytokine levels in IGA
223 subgroups. There is a distinct group of patients across all IGA severities that has low systemic
224 levels of all cytokines. In addition, many more severe outliers have several magnitude higher
225 levels across the entire cytokine panel as compared to milder cases.

226 **Discussion**

227 Defining AD subtypes has been a debated subject in the field. Definitions analogous to asthma
228 have been previously used based on elevated IgE: with presence ("extrinsic") or absence
229 ("intrinsic") of increased IgE²⁸. Now, endotypes defined by different age groups, ethnicities and
230 according to IgE levels and FLG mutation status are in the scope of discussions⁸. Rare
231 information is available regarding endotypes and different stages of AD in one population.
232 According to epidemiological studies, mild AD is the most common type of AD, affecting
233 approximately 60% of AD cases. The factors underlying severity are not well understood. We
234 present here clinical and genetic evidence supporting the concept of AD in different stages being
235 composed of distinct endotypes. Clinical features suggest milder and severe AD appear to be
236 distinct entities that can be differentiated by five clinical features from the SCORAD
237 index. More severe AD is associated with a higher prevalence of mutation burden in the FLG
238 skin barrier structural protein. These data are consistent with previous investigations, including a
239 study in Denmark on (n=470) patients with AD²⁹, as well as extensive studies of *FLG* gene⁵.
240 We found that more severe AD is associated with significantly higher count of eosinophils as
241 compared to milder AD. Eosinophils are mediators of the inflammatory response and are
242 responsible for recruiting other immune cells in the lesions. As such, it is likely that severe
243 pruritus associated with both mild and severe AD may have different mediators (inflammation,
244 skin barrier disturbance). Based on our findings we hypothesize that the contribution of SP in
245 mild AD, in generating and transmitting the pruritic signal, may be relatively more significant
246 than that seen in severe AD where inflammation dominates. Through whole genome sequence
247 analysis we have also discovered that polymorphisms in the *IL5Ra* gene are associated with
248 higher count of eosinophils in this population of AD patients. The association between

249 eosinophils and IL5RA has been previously reported in asthmatic patients³⁰. Here we find the
250 association by gene-centric testing between the two severity groups. This is in agreement with a
251 reported association of rs2522411 variant in the IL-5 gene which was significantly associated
252 with extrinsic AD³⁰. When evaluating IL genes we detect IL5RA rare variants further
253 differentiating between severities, with rare IL5RA variants accumulating in the more severe
254 cases.

255 The described findings lend credence to the existence of endotypes within AD that are
256 manifested clinically and are becoming more understood in terms of underlying mechanisms.
257 These findings may have implications for both diagnosis and treatment course of the disorder. As
258 seen in (Welsh et al. 2020, unpublished) a robust anti-pruritic effect was observed in only the
259 IGA1/2 population while the difference from placebo was not significant in the more severe IGA
260 population. Endotype analyses define the underlying clinical and genetic factors of mild versus
261 more severe AD, and would indicate that the immune response and skin barrier dysfunction
262 tends to be increased in more severe AD. This may mean treating such patients may require more
263 immunosuppressive/immunomodulating therapies. In contrast, mild patients without such
264 underlying factors may be better served with direct targeted therapies such as an anti-pruritic
265 agent addressing the severe itch they may still experience despite their lesions being almost clear
266 or mild. Further attempts to define AD endotypes should be made to define the optimal
267 therapeutic approach, moving towards precision medicine-based treatment of AD based on
268 clinical, molecular, and genetic characteristics.

269 **Acknowledgements**

270 We are grateful to all the study participants and all whom made the study possible

271 **Figure legend**

272 **Figure 1.** Atopic dermatitis endotypes

273 **Figure 2.** Differences between mild and moderate to severe subtypes in terms of clinical feature
274 space

275 **Figure 3.** FLG LOF variants across IGA endotypes

276 **Figure 4.** Cytokine panel at baseline (ratio to reference range)

277 **Figure 5.** Individual cytokine scatter plots

278 **Table legend**

279 **Table 1.** Baseline demographic and clinical characteristics


	Overall
	N=341
Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI (kg/m ²)	28.2 (5.2)
WI-NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 ⁹ /L)	0.25 (0.2)
FLG LOF	51 (15.4)
IgE, n (% of ≥100 kU/L)	167 (49.0)

281 **References**


- 282 1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America
283 Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic
284 Dermatitis in the US Adult Population. *J Invest Dermatol.* 2019;139(3):583-590.
285 doi:10.1016/j.jid.2018.08.028
- 286 2. Stein SL, Cifu AS. Management of Atopic Dermatitis. *JAMA.* 2016;315(14):1510-1511.
287 doi:10.1001/JAMA.2016.1459
- 288 3. Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic
289 rhinitis, and atopic dermatitis. *Arch Dis Child.* 1992;67(8):1018-1022.
290 doi:10.1136/adc.67.8.1018
- 291 4. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009.
292 *J Allergy Clin Immunol.* 2010;125(1):16-29.e1-11; quiz 30-1.
293 doi:10.1016/j.jaci.2009.11.008
- 294 5. Chen H, Common JEA, Haines RL, et al. Wide spectrum of filaggrin-null mutations in
295 atopic dermatitis highlights differences between Singaporean Chinese and European
296 populations. *Br J Dermatol.* 2011;165(1):106-114. doi:10.1111/j.1365-2133.2011.10331.x
- 297 6. Gao P-S, Rafaels NM, Hand T, et al. Filaggrin mutations that confer risk of atopic
298 dermatitis confer greater risk for eczema herpeticum. *J Allergy Clin Immunol.*
299 2009;124(3):507-513, 513.e1-7. doi:10.1016/j.jaci.2009.07.034
- 300 7. Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The Genetics of Chronic Itch: Gene
301 Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J*
302 *Invest Dermatol.* 2018;138(6):1311-1317. doi:10.1016/j.jid.2017.12.029
- 303 8. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin Barrier and Immune Dysregulation
304 in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. *J Allergy*
305 *Clin Immunol Pract.* 2014;2(4):371-379. doi:10.1016/J.JAIP.2014.03.006
- 306 9. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. *Allergy, Asthma*
307 *Clin Immunol.* 2016;12(1):52. doi:10.1186/s13223-016-0158-5
- 308 10. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin
309 (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol.* 2012;130(4):912-
310 917. doi:10.1016/j.jaci.2012.07.008
- 311 11. Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of Atopic Dermatitis
312 with Filaggrin loss-of-function variant status. *Sci Rep.* 2020;10(1):2721.
313 doi:10.1038/s41598-020-59627-7
- 314 12. Engebretsen KA, Bandier J, Kezic S, et al. Concentration of filaggrin monomers, its
315 metabolites and corneocyte surface texture in individuals with a history of atopic
316 dermatitis and controls. *J Eur Acad Dermatology Venereol.* 2018;32(5):796-804.
317 doi:10.1111/jdv.14801
- 318 13. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. *Genes Encoding Structural*
319 *Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene*
320 *Complex ("Epidermal Differentiation Complex") on Human Chromosome*
321 *Lq21.* Vol 106.; 1996. doi:10.1111/1523-1747.ep12338501
- 322 14. Kyriiotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified
323 envelope precursors, S100 proteins and the ‘fused genes’ family. *Exp Dermatol.*
324 2012;21(9):643-649. doi:10.1111/j.1600-0625.2012.01472.x
- 325 15. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal

- 326 cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin*
327 *Immunol.* 2009;124(6):1235-1244.e58. doi:10.1016/j.jaci.2009.09.031
- 328 16. Jensen J-M, Fölster-Holst R, Baranowsky A, et al. Impaired Sphingomyelinase Activity
329 and Epidermal Differentiation in Atopic Dermatitis. *J Invest Dermatol.* 2004;122(6):1423-
330 1431. doi:10.1111/j.0022-202X.2004.22621.x
- 331 17. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin
332 lesions shows overexpression of an epidermal differentiation gene cluster in the
333 alternative pathway and lack of protective gene expression in the cornified envelope. *Br J*
334 *Dermatol.* 2005;152(1):146-149. doi:10.1111/j.1365-2133.2005.06352.x
- 335 18. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene
336 encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic
337 eczema. *Nat Genet.* 2007;39(5):650-654. doi:10.1038/ng2020
- 338 19. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J*
339 *Allergy Clin Immunol.* 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668
- 340 20. Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares
341 similar T-cell clones with lesional tissues. *Allergy.* 2017;72(12):2017-2025.
342 doi:10.1111/all.13223
- 343 21. Ständer S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the
344 treatment of chronic pruritus. *Br J Dermatol.* 2019;181(5):932-938.
345 doi:10.1111/bjd.18025
- 346 22. Azimi E, Reddy VB, Shade K-TC, et al. Dual action of neurokinin-1 antagonists on Mas-
347 related GPCRs. *JCI Insight.* 2016;1(16):e89362. doi:10.1172/jci.insight.89362
- 348 23. Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic
349 markers of the inflammatory process in atopic dermatitis: relation to the severity and
350 pruritus. *Adv Dermatology Allergol.* 2013;5(5):286-292. doi:10.5114/pdia.2013.38357
- 351 24. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for
352 atopic eczema research: results of the HOME II meeting. *Allergy.* 2012;67(9):1111-1117.
353 doi:10.1111/j.1398-9995.2012.02874.x
- 354 25. Severity Scoring of Atopic Dermatitis: The SCORAD Index. *Dermatology.*
355 1993;186(1):23-31. doi:10.1159/000247298
- 356 26. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of
357 healthy subjects. *Mediators Inflamm.* 2013;2013. doi:10.1155/2013/434010
- 358 27. Hänel KH, Cornelissen C, Lüscher B, Baron JM. Cytokines and the skin barrier. *Int J Mol*
359 *Sci.* 2013;14(4):6720-6745. doi:10.3390/ijms14046720
- 360 28. Karimkhani C, Silverberg JI, Dellavalle RP. Defining intrinsic vs. extrinsic atopic
361 dermatitis. *Dermatol Online J.* 2015;21(6).
362 <http://www.ncbi.nlm.nih.gov/pubmed/26158358>. Accessed March 11, 2020.
- 363 29. Holm JG, Agner T, Clausen M-L, Thomsen SF. Determinants of disease severity among
364 patients with atopic dermatitis: association with components of the atopic march. *Arch*
365 *Dermatol Res.* 2019;311(3):173-182. doi:10.1007/s00403-019-01895-z
- 366 30. Namkung J-H, Lee J-E, Kim E, et al. IL-5 and IL-5 receptor alpha polymorphisms are
367 associated with atopic dermatitis in Koreans. *Allergy.* 2007;62(8):934-942.
368 doi:10.1111/j.1398-9995.2007.01445.x
- 369


A **SCORAD - total score**




B








C **EOS by IGA**




D








FLG LOF's














IGA1+2

IGA3

IGA4



GMCSF**IFNg****IL12p70****IL1B****IL4****IL5****IL6****IL8****IL13****IL23****TNFa****IL17A**